

DATE:

12-11-03

9679 '03 DEC 16 P3:16

NOTE TO
DOCKET NO.:

2000N-1652

SUBJECT:

Requirements for Submission of Labeling
for Human Prescription Drugs and Biologics
in Electronic Format; final rule

PUBLICATION DATE:

December 11, 2003

On September 30, 1993, President Clinton signed Executive Order 12866--Regulatory Planning and Review. This Executive Order sets forth the Administration's principles and requirements for the Federal regulatory process. Under section 6(a)(3)(E) of the Executive Order, for "significant regulatory actions," Federal agencies must make certain information available to the public after publication of the regulatory action in the Federal Register.

Pursuant to the Executive Order, FDA has attached, for significant regulatory actions, in this docket the following information:

- 1) A copy of the draft regulatory action as submitted to the Office of Management and Budget's (OMB) Office of Information and Regulatory Affairs (OIRA) for review including any materials or assessments, required by the Executive Order, that accompanied the draft (TAB A);
- 2) The substantive changes between the draft submitted to OIRA for review and the action subsequently announced, if any (TAB B); and
- 3) Those changes in the regulatory action that were made at the suggestion or recommendation of OIRA, if any (TAB B).

David F. Tishler
Regulations Policy and
Management Staff
(HF-26)

Attachment(s)

00N-1652

REF 2